Journal Mobile Options
Table of Contents
Vol. 4, Suppl. 1, 1998
Issue release date: October 1998
Eur Addict Res 1998;4(suppl 1):32–36
(DOI:10.1159/000052040)

Buprenorphine Maintenance in Pregnant Opiate Addicts

Fischer G. · Etzersdorfer P. · Eder H. · Jagsch R. · Langer M. · Weninger M.
a Department of General Psychiatry, b Department of Gynaecology and Obstetrics, c Department of Pediatrics, University Hospital of Psychiatry, Vienna, Austria

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Opioid maintenance agents such as methadone and slow-release morphine have provided beneficial effects in pregnant opioid-dependent women in both themselves and their child. However, one of the major drawbacks involved with these agents is that they cause an increase in the severity of neonatal abstinence syndrome (NAS) when compared to mothers using heroin. Consequently, a trial was performed to investigate the effects of buprenorphine use during pregnancy. A total of nine pregnant opioid-dependent women were transferred from either a mean daily dose of 39.7 mg methadone or 400 mg slow-release morphine to a mean daily dose of 8.1 mg buprenorphine. The buprenorphine-maintained patients were integrated into an already established outpatient maintenance treatment programme covering all aspects of prenatal and perinatal care. Results demonstrated that buprenorphine administration in opioid-dependent pregnant patients is efficacious and well tolerated. Babies born to buprenorphine-maintained patients had birthweight and Apgar scores within the normal range (2,500–4,500 g and 9–10, respectively) and no evidence of opioid-related NAS was observed. The results from this preliminary study indicate the potential for buprenorphine maintenance therapy in pregnant addicts, although further research is required to confirm this hypothesis.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Benowitz NL: Nicotine replacement therapy during pregnancy. J Am Med Ass 1991;266:3174–3177.
  2. Fagerström KO: Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addictive Behaviours 1978;3:235–241.
  3. Jones KL, Smith DW: Recognition of the fetal alcohol syndrome in early infancy. Lancet 1973;2:99–101.
  4. Frank DA, Bresnahan K, Zuckerman B: Maternal cocaine use: impact on child health and development. Adv Pediatr 1993;40:65–99.
  5. Finnegan LP, Ehrlich SM: Maternal drug abuse during pregnancy: evaluation and pharmacotherapy for neonatal abstinence. Mod Methods Pharmacol Test Eval Drugs Abuse 1990;6:255–263.
  6. Finnegan LP, Kaltenbach K: Neonatal abstinence; in Hoekelman RA, Friedman SB, Nelson N, Siedel HM (eds): Primary Pediatric Care. St Louis, Mosby, 1992, pp 1367–1378.
  7. Kaltenbach K, Finnegan LP: Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehav Toxicol Teratol 1986;8:353–355.

    External Resources

  8. Cooper JR: Ineffective use of psychoactive drugs: methadone treatment is no exception. J Am Med Ass 1992;267:281–282.
  9. Blinick G, Jerez E, Wallach RC: Methadone maintenance, pregnancy and progeny. J Am Med Ass 1973;225:477–479.
  10. Doberczak TM, Kandall SR, Friedmann P: Relationships between maternal methadone dosage, maternal-neonatal methadone levels and neonatal withdrawal. Obstet Gynecol 1993;81:936–940.
  11. Kaltenbach K, Finnegan LP: Perinatal and developmental outcome of infants exposed to methadone in utero. Neurotoxicol Teratol 1987;9:311–313.
  12. Kaltenbach K, Thakur N, Weiner S, Finnegan LP: The relationship between maternal methadone dose during pregnancy and infant outcome. Pediat Res Abstracts 1990.
  13. Fischer G, Presslich O, Diamont K, Schneider C, Pezawas L, Kasper S: Oral morphine-sulphate in treatment of opiate dependent patients. Alcoholism 1996;32:35–43.
  14. Etzesdorfer P, Fischer G, Eder H, Jagsch R, Schmidt-Mohe K, Gombas W: Comparison of morphine and methadone maintenance in pregnant opiate addicts. Am Psychiat Ass. San Diego, 1997: Abstract p 148.
  15. Jasinski DR, Pevnick JS, Griffith JD: Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiat 1978;35:501–516.
  16. Nutt DJ: Receptor pharmacology of buprenorphine. Res Clin Forums 1997;19(2):9–15.
  17. Chapleo CB: Alternate-day dosing. Res Clin Forums 1997;19(2):39–42.
  18. Fudula PJ, Jaffe JH, Dax EM, Johnson RE: Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioural effects of daily and alternate day administration and abrupt withdrawal. Clin Pharmacol Ther 1990;47:525–534.
  19. Reisinger M: Treatment of four pregnant heroin addicts with buprenorphine: History and outcome. Presented at College on Problems of Drug Dependence, 57th Annual Scientific Meeting, Scotsdale, Arizona, 1995, Abstract, p 116.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50